Congress trades
Nektar Therapeutics (NKTR)
About Nektar Therapeutics
from the company's filings and listing- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Chief executive
- Howard W. Robin
- Employees
- 63
- Listed since
- May 3, 1994
- Market value
- $2.1B
- Price to earnings
- -
- Earnings per share
- -$4.75
- Dividend yield
- -
Earnings
6 reported quarters · next on Nov 5, 2026| Quarter | EPS | EPS expected | Revenue | Revenue expected | Result |
|---|---|---|---|---|---|
| Q2 FY2026reported Aug 13, 2026 | -$1.23 | -$1.97 | $10.1M | $10.4M | EPS beatRevenue miss |
| Q1 FY2026reported May 7, 2026 | -$1.82 | -$1.58 | $10.9M | $10.7M | EPS missRevenue beat |
| Q4 FY2025reported Mar 12, 2026 | -$1.78 | -$2.47 | $21.8M | $10.2M | EPS beatRevenue beat |
| Q3 FY2025reported Nov 6, 2025 | -$1.85 | -$2.85 | $11.8M | $10.1M | EPS beatRevenue beat |
| Q2 FY2025reported Aug 7, 2025 | -$2.95 | -$3.03 | $11.2M | $9.5M | EPS beatRevenue beat |
| Q1 FY2025reported May 8, 2025 | -$3.60 | -$2.56 | $10.5M | $15.4M | EPS missRevenue miss |
Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag marked GAAP compares a GAAP figure the company reported with an adjusted consensus, two different measures, so a one-time gain or charge can move it either way; basis unverified means we could not classify the reported figure. A flag reads n/a only when a number is missing. An estimate is a forecast made by analysts, not a company target.
Executive pay
as filed for 2025 · proxy filed Apr 24, 2026| Executive | Salary | Stock awards | Other | Total |
|---|---|---|---|---|
| Howard W. RobinPresident and Chief Executive Officer | $1.1M | $942K | $4.2M | $6.3M |
| Jonathan Zalevsky, Ph.D.Chief Research and Development Officer | $718K | $272K | $1.3M | $2.3M |
| Sandra GardinerInterim Chief Financial Officer | $0 | $0 | $686K | $686K |
The summary compensation table from the 2025 proxy statement, current executives only. 1 executive who has since left the company is named in that filing and not shown here. Read the filing
Institutional holders
13F positions as of Jun 30, 2026| Holder | Value | Shares | Change | Of company |
|---|---|---|---|---|
| FMR LLC | $353.8M | 5,067,920 | +17.8% | 15.33% |
| Two Seas Capital LP | $215.9M | 3,092,234 | +57.8% | 9.35% |
| Blackrock, Inc. | $205.4M | 2,941,851 | +324.7% | 8.90% |
| BVF Inc/Il | $166.9M | 2,391,075 | -6.6% | 7.23% |
| Vanguard Capital Management LLC | $104.5M | 1,496,849 | +25.0% | 4.53% |
| Two Sigma Investments, LP | $83.9M | 1,202,004 | +29.1% | 3.64% |
| Vestal Point Capital, LP | $69.8M | 1,000,000 | +250.9% | 3.03% |
| Morgan Stanley | $65.4M | 936,560 | +42.0% | 2.83% |
| State Street Corp | $63.5M | 909,679 | +271.7% | 2.75% |
| Geode Capital Management, LLC | $61.5M | 881,306 | +154.1% | 2.67% |
| Susquehanna International Group, LLP | $57.5M | 823,700 | +90.2% | 2.49% |
| Prosight Management, LP | $56.5M | 810,000 | +10.2% | 2.45% |
A 13F reports long US equity positions 45 days after the quarter ends, so these are positions as they stood on Jun 30, 2026. For a manager's whole book see the fund directory.
GetSignal watches Form 4 and STOCK Act filings and pushes each one to your phone as it is published, with the history behind it. Free on iOS and Android.
Congress trades in NKTR
7 disclosures of 7 on record · median 37d of the 45 allowed| Member | Type | Action | Amount disclosed | Since the trade | Trade date | Disclosed | Delay |
|---|---|---|---|---|---|---|---|
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | -76.9%S&P +154.7% · vs S&P 500 -231.5% | Sep 16, 2019 | Oct 16, 2019 | 30d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | -85.4%S&P +170.2% · vs S&P 500 -255.6% | Jun 5, 2019 | Jul 11, 2019 | 36d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | -85.6%S&P +178.4% · vs S&P 500 -264.0% | Jun 3, 2019 | Jul 11, 2019 | 38d |
| Josh GottheimerJointFiled late | Stock | Sale | $1,001 - $15,000 | -91.2%S&P +176.9% · vs S&P 500 -268.1% | Jun 21, 2018 | Oct 2, 2018 | 103d |
| Josh GottheimerJointFiled late | Stock | Purchase | $1,001 - $15,000 | -91.8%S&P +175.0% · vs S&P 500 -266.8% | Jun 6, 2018 | Oct 2, 2018 | 118d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | -93.7%S&P +186.3% · vs S&P 500 -280.1% | May 8, 2018 | Jun 8, 2018 | 31d |
| Ro Khanna | Stock | n/a | $1,001 - $15,000 | -95.1%S&P +193.1% · vs S&P 500 -288.2% | Apr 3, 2018 | May 10, 2018 | 37d |
Since the trade: the stock's move from the trade date to the latest close we hold, as of Sep 10, 2026, an estimate, with the S&P 500 over the same window and the difference against it. The figures describe the stock after the trade, not the member's result: the filing carries a band, not a fill, and a sale keeps the same sign, so a positive figure after a sale means the stock kept rising. An option row carries the underlying stock's move. A row marked n/a has no market price. Not investment advice.
Questions
Which members of Congress have traded NKTR?
Ro Khanna, Josh Gottheimer disclosed NKTR transactions in the filings shown here.
How quickly are NKTR trades disclosed?
Congressional disclosures took a median of 37 days, against the 45 the STOCK Act allows.
How to read a STOCK Act filing
WHAT THE FILING ACTUALLY SAYS
Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.
Data as of Sep 10, 2026.